a) administering a single oral dose of budiodarone or a pharmaceutically acceptable salt thereof to said patient in an amount from about 900 mg to about 2,000 mg, wherein the amount is sufficient to provide for a peak budiodarone blood plasma concentration in said patient of at least about 50 ng/mL and maintain a budiodarone blood plasma concentration in said patient of at least about 13 ng/mL for at least 6 hours wherein said patient's AFib heart rhythm cardioverts to sinus rhythm; and

b) monitoring a heart rhythm of said patient, subsequent to said administering, until the budiodarone blood plasma concentration is measured to be below about 20 ng/mL.